在Trypanosoma cruzi中对不同血红素来源的转录组反应
Evelyn Tevere1, María G Mediavilla1, Cecilia B Di Capua1
1Instituto de Biología Molecular y Celular de Rosario (IBR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)- Universidad Nacional de Rosario (UNR). Ocampo y Esmeralda, 2000, Rosario, Argentina.
bioRxiv : the preprint server for biology
|August 12, 2025
概括
导致查加斯病的Trypanosoma cruzi寄生虫必须获得heme. 补充血红素或血红素等血红素来源引发了明显的基因表达变化,揭示了寄生虫的脆弱性.
科学领域:
- 寄生虫学的寄生虫学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 血红素对于大多数有机体来说是必不可少的,但像Trypanosoma cruzi这样的寄生虫无法合成它.
- T. cruzi必须从宿主那里获得血,这使得这个过程对于生存至关重要.
- 在昆虫载体的中肠中,T. cruzi epimastigotes遇到自由的血红素和血红蛋白.
研究的目的:
- 研究不同血红素来源 (血红素与血红素) 如何影响T. cruzi epimastigote基因表达.
- 为了识别参与血红素获取和代谢的基因,以响应血红素的可用性.
- 为了描述一种新型的血红素反应性血红蛋白,TcCRAL/TRIO.
主要方法:
- 血红素饥饿,然后补充血红素或血红蛋白.
- 在补充剂后4小时和24小时进行RNA测序.
- 生物信息学分析以确定差异表达的基因.
主要成果:
- 血红素补充剂诱导了T. cruzi. 的早期和明显的转录反应.
- 被识别的基因子集是独特或普遍由血红蛋白和血红蛋白调节的.
- 发现了一种新型的血红素反应性血红蛋白,TcCRAL/TRIO.
结论:
- 血红素的获取是T. cruzi.的一个关键过程和潜在的脆弱性.
- 了解血红素调节的基因表达提供了对寄生虫生物学的见解.
- 这些发现可能会导致查加斯病的新治疗点.
更多相关视频
06:13Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
Published on: July 31, 2019
9.1K
08:48In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
3.4K
相关概念视频
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...